Diagnoses 🩺📋
These are the diagnoses I have, some cogenital, others new since Long Covid. Pulled from my own records across my primary care health system, a tertiary referral center, another regional health system, an ENT specialty clinic, a neuro-optometry clinic, and a general optometry clinic — then deduped and grouped by system.
This isn’t every label that’s ever been applied to me. It’s the active problem list as of the most recent record sync, plus a small Inactive/Resolved section for context. Some entries (especially the older “anxiety” ones) predate the COVID infection in November of 2024; most of the more recent neurological, eye, and ENT entries do not.
This is not medical advice, this is a collection of my diagnostic records.
Neurological & Cognitive
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Progressive mild cognitive impairment | G31.84 | 2026-04-29 | Documented by neurology as significantly affecting daily functioning. MoCA 25/30. Etiology unclear; differential includes neurodegenerative, post-COVID sequelae, medications, anxiety/depression, and autoimmune/metabolic causes. Struthers Parkinson's Center (2026-07-16) attributed it to long COVID: P-tau blood test negative, major neurodegenerative diseases (Parkinson's, Alzheimer's, ALS, MS) ruled out, DaTscan deferred as not indicated. Repeat formal cognitive testing considered reasonable to track stability |
| Chronic gait instability | R26.81 | 2026-04-29 | Episodes of leg weakness and falls; multifactorial, attributed to vestibular dysfunction and deconditioning. Cane used for safety |
| Distal small fiber neuropathy — suspected | Pending | 2026-04-08 | Thermoregulatory sweat test (Mayo) showed anhidrosis of toes and hypohidrosis of feet. Medication confounders (meclizine, duloxetine, cetirizine, mirtazapine, fexofenadine) cannot be excluded |
| Persistent postural-perceptual dizziness (PPPD) | H81.8X9 | Chronic dizziness syndrome often triggered by acute vestibular events | |
| Migraine with vertigo | G43.109 | Vestibular migraine | |
| Chronic migraine without aura | G43.709 | 2026-06-08 | Neurology (2026-07-21): partial response to Emgality, down from daily to about five a week, with brief breakthrough flares. Sumatriptan ineffective; ubrogepant and rimegepant samples given for acute use. Botox discussed if Emgality stops working |
| Autonomic dysfunction | G90.9 | 2026-03-18 | Carried by several providers through 2026; Struthers Parkinson's Center (2026-07-16) describes episodic sympathetic surges as part of the post-COVID picture |
| Dizziness | R42 | 2026-05-01 | Added during the April–May 2026 ER cluster |
| Restless legs syndrome — chronic, refractory | G25.81 | 2026-02-02 | Pramipexole losing efficacy; gabapentin and pregabalin previously caused edema and worsened tremors. Augmentation risk discussed. Now followed by a sleep specialist: continuing pramipexole 0.75 mg at 9 pm (ropinirole was noted at the June 2026 neurology visit but not started). Ferritin 150 ng/mL (2026-05-15), within range |
| Attention and concentration deficit | R41.840 | 2026-02-12 | Post-viral cognitive change |
| ADHD, inattentive type | F90.0 | 2025-02-11 | Previously coded as ADD (F98.8); recoded by psychiatry 2026-06-16. On guanfacine ER |
| Chronic neck pain | G89.29 |
Mental Health
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Anxiety disorder due to general medical condition with panic attack | F41.0 | 2026-04-25 | ICD F06.4 framing — the chart documents the anxiety as physiologically driven, not idiopathic |
| Major depressive disorder, recurrent episode, moderate | F33.1 | 2026-04-22 | Re-noted during the April 2026 ER visits. Severity has swung since: in partial remission (F33.41, 2026-06-16), moderate again in August, and a severe episode without psychotic features (F33.2) recorded 2026-09-16 |
| Generalized anxiety disorder | F41.1 | 2017-10-28 | Pre-existing |
| Adjustment disorder with mixed anxiety and depressed mood | F43.23 | 2017-12-22 | Pre-existing |
ENT & Vestibular
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Pulsatile tinnitus | H93.A9 | Heart-beat-synchronized tinnitus | |
| Hyperacusis, left ear | H93.232 | Sound sensitivity | |
| Mixed conductive and sensorineural hearing loss, left ear | H90.72 | Right ear unaffected. Recorded as sensorineural hearing loss of the left ear on 2026-09-23 | |
| Vestibular dysfunction of left ear | H81.92 | 2025-07-10 | Primary care marked the unspecified version inactive in 2025; re-added as left-ear vestibular dysfunction and active on the primary care problem list as of 2026-09-29. Neurology has carried it throughout |
| Clicking tinnitus of left ear | H93.12 | 2026-04-13 | Active on the problem list through 2026-08-31 |
| Perforation of left tympanic membrane | H72.92 | 2026-05-20 | Post-operative after the PLF repair; did not heal (paper patch 2026-06-19). Repaired surgically 2026-07-16, followed by more ear popping and tinnitus. Left-ear drainage (otorrhea, H92.12) recorded 2026-09-30 |
| Cochlear hydrops | H83.8X9 | 2026-03 | ENT attribution for vestibular and ear symptoms; treated with diuretic and betahistine. Referred to ENT for possible third-window evaluation |
| Perilymphatic fistula (PLF) | H83.1X2 | 2026-05 | Confirmed by ENT; surgical repair (exploratory tympanotomy, FlexHD tympanoplasty, round-window reinforcement, lysis of adhesions) performed May 2026. Improved hearing post-op but did not improve dizziness. Eardrum has not healed well since (see tympanic membrane perforation) |
Vision & Eye
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Intermittent alternating esotropia | H50.32 | 2025-01-13 | Managed with prism correction; first diagnosed at neuro-optometric eval |
| Divergence insufficiency | H51.8A | 2025-01-13 | Eso at distance, exo at near |
| Vertical heterophoria | H50.53 | 2025-01-13 | Treated with vertical prism in glasses |
| Deficiency of saccadic eye movements | H55.81 | 2025-01-13 | Eye-movement deficit consistent with post-concussion / post-COVID patterns |
| Visual field defect, constriction OU | H53.483 | 2025-11-12 | Bilateral visual field constriction confirmed by automated perimetry |
| Abnormal oculomotor study | R94.113 | 2025-11-12 | Per sensorimotor examination at general optometry clinic |
| Esophoria, right eye | H50.51 | 2025-11-12 | |
| Hypermetropia (farsightedness), both eyes | H52.03 | 2025-01-13 | |
| Presbyopia | H52.4 | 2025-01-13 | |
| Posterior subcapsular polar cataract, right eye | H25.041 | 2025-11-12 | First flagged by general optometry clinic 2025-11-12; added to primary care problem list 2026-04-02 |
| Variable esodeviation with binocular diplopia | H53.2 | 2026-05-20 | Neuro-ophthalmology characterization of the alternating esotropia: alignment varies across exams and prism prescriptions; horizontal/diagonal diplopia worse at distance |
| Ocular myasthenia gravis — suspected, under workup | Pending | 2026-05-20 | Raised by neuro-ophthalmology on 2026-05-20 due to variable ocular alignment across exams. Screening MG labs came back normal per the Parkinson's center (neurology calls the panel borderline); purely ocular MG has ~50% false-negative rate. Pyridostigmine trial stopped for GI side effects and no benefit for diplopia. Double vision still worsening as of July 2026 |
Cardiovascular & Metabolic
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Metabolic syndrome | E88.810 | 2026-03-25 | Constellation: dyslipidemia + hyperglycemia tendency (prediabetes, R73.03, coded April 2026). Started Wegovy (semaglutide, a GLP-1) in September 2026 |
| Hypertension | I10 | 2026-02-26 | Masked pattern: stage II when self-measured in clinic, stage I when staff take it. On losartan |
| Hyperlipidemia | E78.5 | 2024-02-09 | Pre-existing. Atorvastatin stopped June 30, 2026 over muscle aches and an elevated CK (R74.8); switched to rosuvastatin 10 mg Aug 25, 2026 |
| Hypokalemia, recurrent | E87.6 | 2024-09-18 | Serum potassium has swung between 2.8 and 4.0 mmol/L; on potassium chloride and potassium citrate. Primary care coded potassium-wasting nephropathy (N25.89) in June 2026, but nephrology (July–Aug 2026) could not confirm renal potassium wasting while potassium was normal on supplements — cause still unclear. Serum aldosterone 5 (2026-07-07). Hypoaldosteronism (E27.40) was coded in Aug 2026 as the prior-authorization diagnosis for Wegovy; no endocrine workup is documented |
| Anemia, unspecified | D64.9 | 2026-05-11 | Low hemoglobin from May 2026; coded as anemia 2026-06-30 |
Musculoskeletal
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Cervical radiculopathy | M54.12 | 2026-02-24 | |
| Osteoarthritis of cervicothoracic spine | M47.813 | 2026-04-15 | Also coded as cervicothoracic spondylosis (M47.893) 2026-06-25. Cervical interlaminar epidural steroid injection 2026-06-18 brought neck pain from 6/10 to 4/10 |
| Spondylosis of cervical region without myelopathy or radiculopathy | M47.812 | 2025-06-13 | |
| Lumbar spina bifida without hydrocephalus | Q05.7 | 2025-01-13 | Congenital |
| Spina bifida occulta | Q76.0 | 2026-02-02 | Congenital |
| Cerebellar tonsillar ectopia | Pending | 2026-04-26 | Incidental MRI brain finding — does not meet criteria for Chiari malformation |
Other
| Diagnosis | ICD-10 | First noted | Notes |
|---|---|---|---|
| Obstructive sleep apnea, mild | G47.33 | 2026-09-29 | Repeat in-lab polysomnogram (Sept 2026): AHI 13, RDI 13, oxygen nadir 86%, sleep efficiency 87%. Up from AHI 2 and nadir 91% on the Feb 2025 study. Starting an APAP trial (5–15 cm H₂O) with an 8-week follow-up and data download |
| Chronic insomnia | F51.04 | 2024-11 | Post-COVID; followed by sleep medicine and a sleep psychologist. CBT-I not effective; sleep aids (eszopiclone, doxepin, trazodone) work at first, then lose effect. Also coded Other insomnia (G47.09) during the April–May 2026 ER cluster |
| Eosinophilic esophagitis — suspected, under evaluation | Pending | 2026-06-19 | Raised by ENT as a possible explanation for dysphagia; endoscopy recommended. Considered less likely while on Xolair, famotidine, Allegra, and Zyrtec |
| Gastroesophageal reflux disease | K21.9 | 2026-07-30 | On famotidine |
| Shortness of breath | R06.02 | 2026-09-01 | On the active primary care problem list as of 2026-09-29 |
| Chronic urticaria | L50.8 | 2024-09-03 | Managed by allergy; on Xolair, Allegra, and Zyrtec |
| Irritable bowel syndrome with diarrhea | K58.0 | 2023-11-09 | Pre-existing |
| Mild intermittent asthma | J45.20 | Pre-existing; on Symbicort |
Inactive or Resolved (for context)
| Diagnosis | ICD-10 | Status | As of | Notes |
|---|---|---|---|---|
| Long COVID | U09.9 | Inactive (primary care) / Active (neuro-optometry, neurology, Parkinson's center) | 2026-07-16 | Primary care system marked Inactive 2025-07-10. Neuro-optometry has it documented Active across three visits (2025-01-13, 2025-05-01, 2025-08-01) and explicitly attributes binocular vision dysfunction to it. Neurology (2026-04-29) explicitly carries 'Chronic post-COVID syndrome' as an active assessment — referred to Mayo Long COVID clinic urgent waitlist and HCMC autonomic lab. Struthers Parkinson's Center (2026-07-16) assessed 'Long COVID syndrome with neurological manifestations': cognitive impairment, balance and gait disorder, muscle weakness, autonomic dysfunction, and sleep disturbance |
| Balance problem | R26.89 | Inactive | 2025-07-10 | |
| Psychophysiologic insomnia | F51.04 | Resolved | 2026-02-11 | |
| Other somatoform disorders | F45.8 | Resolved | 2026-02-11 | |
| Mechanical low back pain | M54.59 | Resolved (primary care) / Active (neurology) | 2026-02-11 | Primary care marked Resolved 2026-02-11; neurology still has it on the active problem list as of 2026-05-20 |
Workup completed
Tests and imaging that have been performed during this workup — what's been ruled out or characterized so far. Mostly unrevealing, which is itself part of the Long Covid story.
| Test / Study | Date | Result |
|---|---|---|
| Polysomnogram (in-lab, repeat) | 2026-09 | Mild obstructive sleep apnea: AHI 13, RDI 13, oxygen nadir 86%. Total sleep 425 of 488 min (efficiency 87%), sleep latency 26 min, REM latency 154 min; N3 14%, REM 18%. |
| Nephrology potassium workup | 2026-07-07 | Serum potassium 4.0 on supplements; 24-hour urine potassium 68 mmol/L, random urine potassium 40 mmol/L, transtubular potassium gradient 6.3, serum aldosterone 5. Renal potassium wasting not demonstrated while potassium was normal. |
| P-tau blood test | 2026 | Negative (per Struthers Parkinson's Center, 2026-07-16). |
| Myasthenia gravis screening labs | 2026 | Normal per Struthers Parkinson's Center; described as borderline by neurology (2026-07-21). |
| MRI brain (with and without contrast) | 2026-04-26 | Stable. No demyelinating disease. Minor nonspecific T2/FLAIR hyperintensities, unchanged from prior. Mild cerebellar tonsillar ectopia not meeting criteria for Chiari malformation. |
| CT head | 2026-04-06 | No findings on either side to explain inner-ear or disequilibrium symptoms. No 3rd-window phenomenon or bony dehiscence. |
| CT temporal bones (SCDS protocol with Stenvers/Pöschl reformats) | 2026-03-10 | Normal temporal bones bilaterally; left tympanostomy tube in place. (Sensitive to dehiscence, less so to near-dehiscence.) |
| MRA head | 2025-04-25 | No aneurysm, no high-flow vascular malformation, no high-grade stenosis. |
| MRV head | 2025-04-25 | No dural venous sinus thrombosis. |
| MRI cervical spine | 2026-02-04 | Multilevel degenerative changes. Severe right C5-C6 neural foraminal stenosis, moderate right C4-C5. No high-grade spinal canal stenosis. |
| MRI lumbar spine | 2024-08-12 | Multilevel degenerative changes without high-grade canal or foraminal stenosis. |
| EMG, bilateral upper extremities | 2025-09-12 | Normal. No motor radiculopathy, no median/ulnar/radial mononeuropathy. |
| EMG (fasciculation workup) | 2024-06-20 | Benign-appearing fasciculation potentials in calves; consistent with benign fasciculation syndrome. |
| Lumbar puncture | 2025-06-10 | Normal opening pressure. Oligoclonal bands negative, IgG index 0.52, normal protein/glucose, Borrelia negative, VDRL non-reactive. |
| Autoimmune / paraneoplastic antibody panel | 2025–2026 | All antibodies negative — Anti-Hu, Anti-Ri, NMDA-R, GAD65, Aquaporin 4, VGCC, CASPR2, LGI1, GABA-B-R, IgLON5, and others. |
| Rheumatologic / connective-tissue workup | 2026-01-16 | ANCA, MPO, SSA/SSB, C3, C4, CRP, ESR, RF, cryoglobulin — all within normal limits or negative. |
| Exercise stress echocardiogram | 2026-04-06 | Negative for myocardial ischemia. EF 61% rest → 71% peak stress. Normal LV filling pressure at rest and with exercise. 10.9 METS, 90% age-predicted max HR. |
| Holter monitor (24 h) | 2026-04-07 | Sinus rhythm. HR 45–122, average 71. Two patient-triggered events (palpitations, dizziness) showed sinus rhythm with no ectopy. |
| 12-lead EKG | 2026-04-06 | Normal sinus rhythm. Normal ECG. |
| Polysomnogram (in-lab) | 2025-02-11 | AHI 2, RDI 2 (supine AHI 5, REM AHI 6), oxygen nadir 91%. N3 8%, REM 23%. Read as no underlying sleep disorder at the time. |
| Thermoregulatory sweat test | 2026-04-08 | Anhidrosis of toes, hypohidrosis of feet — could suggest distal small fiber neuropathy. Medication effects (meclizine, duloxetine, cetirizine, mirtazapine, fexofenadine) cannot be excluded. |
A note on “Long COVID, Inactive”
You’ll see U09.9 Long COVID listed under Inactive (primary care system) / Active (neuro-optometry clinic). That’s not because Long COVID resolved — my neuro-optometry clinic has documented it as active across three visits (1/13/2025, 5/1/2025, 8/1/2025) and explicitly attributes my binocular vision dysfunction to it. Different providers, same patient, two different “is it still happening?” answers.